7MW4811 (see: Drugmap), a Mtoxin™ (MF6)-based Antibody-drug Conjugate being developed by Mabwell for the Treatment of Solid Tumors has shown positive and compelling pre-clinical efficacy results in solid tumors.
The data was presented as a poster presentation at the 15th World ADC San Diego, held from Nov. 4 to 7, 2024 in San Diego
7MW4811 is developed with Mabwell’s next-generation ADC platform technology (IDDC™), and has demonstrated encouraging anti-tumor effects across a range of solid tumors, including lung, colorectal, pancreatic, and gastric cancers. Notably, it has shown promising therapeutic potential in gastrointestinal tumors.
IDDC™ is a clinically validated site-specific conjugation technology that has been instrumental in the development of ADCs with good homogeneity, efficacy, and safety profiles. Coupled with the novel payload Mtoxin™ (MF6), these ADCs have been further optimized, exhibiting enhanced pharmacodynamics, bystander-killing efficacy, and anti-multidrug resistance capabilities.
Featured image: World ADC 2020. Photo courtesy: © Hanson Wade. Used with permission.
